Order:
  1.  19
    Novel drug candidates targeting Alzheimer’s disease: ethical challenges with identifying the relevant patient population.Erik Gustavsson, Pauline Raaschou, Gerd Lärfars, Lars Sandman & Niklas Juth - 2021 - Journal of Medical Ethics 47 (9):608-614.
    Intensive research is carried out to develop a disease-modifying drug for Alzheimer’s disease. The development of drug candidates that reduce Aß or tau in the brain seems particularly promising. However, these drugs target people at risk for AD, who must be identified before they have any, or only moderate, symptoms associated with the disease. There are different strategies that may be used to identify these individuals. Each of these strategies raises different ethical challenges. In this paper, we analyse these challenges (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   4 citations  
  2.  19
    Should relational effects be considered in health care priority setting?Erik Gustavsson, Niklas Juth, Gerd Lärfars, Pauline Raaschou & Lars Sandman - 2023 - Bioethics 37 (7):668-673.
    It is uncontroversial to claim that the extent to which health care interventions benefit patients is a relevant consideration for health care priority setting. However, when effects accrue to the individual patient, effects of a more indirect kind may accrue to other individuals as well, such as the patient's children, friends, or partner. If, and if so how, such relational effects should be considered relevant in priority setting is contentious. In this paper, we illustrate this question by using disease‐modifying drugs (...)
    Direct download (2 more)  
     
    Export citation  
     
    Bookmark  
  3.  21
    The ethics of disease-modifying drugs targeting Alzheimer disease: response to our commentators.Erik Gustavsson, Pauline Raaschou, Gerd Lärfars, Lars Sandman & Niklas Juth - 2022 - Journal of Medical Ethics 48 (3):193-193.
    In Gustavsson et al,1 we discussed the ethical issues that arise when identifying the relevant population for disease-modifying drugs targeting Alzheimer disease. More specifically, we focused on novel immunotherapies aimed at amyloid β and tau, two relevant biomarkers. The commentaries to our paper2 3 acknowledge our conclusion: screening for AD involve ethical costs that cannot be justified unless a drug with clinically relevant effect becomes available. Since Aduhelm is the only immunotherapy targeting AD currently approved by the Food and Drug (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark